Skinmed最新文献

Zelsuvmi^TM (berdazimer) topical gel has been approved recently for the treatment of molluscum contagiosum (MC) in patients aged ≥1 year. In three phase 3, randomized, double-blind, vehicle-controlled trials of similar design, berdazimer was investigated for the treatment of MC. Berdazimer or vehicle was applied once daily on MC lesions until complete lesion clearance was observed or for up to 12 weeks. Berdazimer demonstrated higher efficacy in achieving the primary outcome at week 12 (Trial 1, berdazimer: 32.4% [144/444] and vehicle: 19.7% [88/447]; Trial 2, berdazimer: 30% [71/237] and vehicle: 20.3% [24/118]; and Trial 3, berdazimer: 26% [61/236] and vehicle: 22% [28/126]), compared to vehicle. Common adverse events were the mild to moderate reactions, including application site pain, dermatitis, exfoliation, erythema, pruritus, and lesions.

As the presurgical size and anatomic location of non-melanoma skin cancer correlates to the complexity of Mohs micrographic surgery (MMS), patients are frequently asked to self-report their preoperative tumor size to aid in efficient scheduling and triage. We aimed to assess the accuracy of patient's self-reported lesion measurements prior to MMS by comparing patient's estimates of lesion size to the measurements taken by a Mohs surgeon. We conducted a retrospective chart review of 1,000 patients who underwent MMS and self-reported their lesion size at a preoperative telehealth visit. The patients reported their lesion size in one dimension (1D)/two dimensions (2D) or using a pencil eraser as a size reference. Patients demonstrated excellent reliability (intra-class correlation coefficient [ICC]: 0.916) while reporting their lesion size in two dimensions, and moderate reliability (ICC: 0.644) while reporting their lesion size in one dimension. Patients had slight agreement (κ = 0.178) with the surgeon's preoperative measurement while using a pencil eraser as a size reference. Dermatology practices must be encouraged to utilize telehealth to obtain presurgical size estimates from patients using 1D or 2D size measurements. By utilizing presurgical size estimates, surgeons can better triage and schedule patients to provide appropriate anticipatory guidance to patients and their caretakers.

A 39-year-old woman presented to the dermatology department in January 2022 with a 3-week history of a progressively enlarging and intensely pruritic erythematous annular nodule on her left hand. The lesion started as a small blister, which was initially presumed to be a flare up of her pompholyx dermatitis. On her physician's advice, she applied clobetasol propionate ointment twice daily for 5 days; however the blister continued to increase in size until it burst, revealing raw inflamed skin. As the patch continued to increase in size, she was prescribed oral ciprofloxacin 500 mg twice a day for 5 days; however, the constantly weeping lesion grew to around 3 cm in diameter. The associated pruritus also became intense, without any response to regular antihistamines and ice application and disturbing patient's sleep. She also applied regular povidone iodine dressings but without any effect. Apart from pompholyx dermatitis, her medical history was significant for hypermobile Ehlers Danlos syndrome type 3 (hEDS).

Various specific and nonspecific dermatologic abnormalities are observed in chronic kidney disease (CKD). Dermatologic manifestations are observed at all stages of CKD and these increase with increasing duration and severity of the renal disease. Most of the studies in the literature have focussed mainly on dermatologic manifestations associated with dialysis and end-stage renal disease. We conducted a cross-sectional study to determine the prevalence, patterns, and risk factors of dermatologic disorders in CKD patients irrespective of clinical stage or status of dialysis.

Pyoderma gangrenosum (PG) is the second most common skin manifestation reported in patients with inflammatory bowel disease (IBD). We performed a single-institution, retrospective study to summarize the clinical features and examine effective treatment regimens and outcomes of PG in IBD patients. We identified 45 patients who presented to our institute between January 1, 2002 and December 31, 2021 with the following criteria: (1) diagnosed with an active PG (ICD9: 686.01, ICD10: L88) during the specified period, (2) aged at least 18 years at the time of diagnosis, (3) had the diagnosis of IBD, and (4) documented treatment regimens/outcomes. In our cohort, 56% of the patients had PG at the site of stoma. Intralesional and oral steroids were the most utilized therapies for peristomal PG (PPG) and non-peristomal PG (NPPG) in 60% and 62% of the patients, respectively. The bowel manifestations were under control at the time of PG diagnosis in 76% of PPG patients, compared to 43% of NPPG patients. Our findings demonstrated that PPG in IBD patients could be managed locally with intralesional steroids only, as the bowel manifestations of PPG patients tend to be under control, compared to those of NPPG patients.

A Caucasian woman in her twenties having asymptomatic papules on the hands for the past 6 months was referred by rheumatology for a skin biopsy. The patient had presented to rheumatologist for arthralgia. On physical examination, multiple, dull red, 2-5-mm papules were observed on her dorsal fingers, with most in the periungual regions. No papules or nodules were discovered on the mucosal membranes or other areas of her skin. Given the presence of characteristic "coral beads" along the periungual regions, the clinical diagnosis of multicentric reticulohistiocytosis (MRH) was rendered. A 4-mm punch biopsy revealed histiocytes with eosinophilic, homogenous, and finely granular "ground glass" cytoplasm.

Filsuvez^® (birch triterpenes) topical gel received approval in 2023 for the treatment of epidermolysis bullosa (EB) in pediatric patients (aged ≥6 months) and adults. It promotes wound healing by modulating inflammation, encouraging new tissue formation, and maintaining the skin barrier. In a randomized, double-blind, controlled, parallel-group, phase III trial (EASE, NCT03068780), 223 patients were randomly assigned to two groups: the first group received treatment with birch triterpenes topical gel (study gel, n = 109), and the second group received treatment with vehicle gel (n = 114). The study gel or vehicle gel was applied as a 1-mm layer to the affected wound surface once every 4 days for 90 days. The primary efficacy endpoint, defined as the first complete closure of the EB target wound by day 45, was achieved at a higher proportion in the study gel group (41.3% [45/109]), compared to the vehicle gel group (28.9% [33/114]). Application site reactions were reported in 7.3% (8/109) of patients in the study gel group and 6.1% (7/114) of patients in the vehicle gel group. It is recommended to apply as a 1-mm layer to the affected wound surface only.

A 15-year-old African-American man (Fitzpatrick skin type V) presented to the outpatient dermatology clinic with a large, verrucous, exophytic mass measuring 3.5 × 2.3 cm on the right lateral side of the posterior flank (Figure 1). The lesion had been increasing in size for several years. His mother had refused a shave excision when he was 9 years old. He also had atopic dermatitis, acanthosis nigricans, and benign melanocytic nevi. He was obese with borderline hypercholesterolemia.